Recently, Morimatsu officially joined the Biologics Pharma Innovation Programme Singapore (BioPIPS). This milestone marks Morimatsu’s deep integration into the global top-tier biopharma innovation ecosystem. It will further expand the company’s capabilities in biopharmaceutical manufacturing, drive agile manufacturing, process optimization, and green sustainable development, and inject new momentum into the high-quality growth of the biopharma industry in Singapore and the broader Asia-Pacific region.
Biologics Pharma Innovation Programme Singapore is led by the Agency for Science, Technology and Research (A*STAR) and supported by the Singapore Economic Development Board (EDB). As an industry-academia-research collaborative platform dedicated to upgrading biopharmaceutical manufacturing technologies, BioPIPS brings together leading global pharmaceutical companies, research institutes, and universities. With a focus on productivity and sustainability, BioPIPS leverages research and innovation to help enterprises enhance their flexibility and resilience, thereby strengthening the competitiveness of biopharmaceutical manufacturing in Singapore and the Asia-Pacific region.
As a core hub for the biopharma industry in the Asia-Pacific region, Singapore is also a pivotal node in Morimatsu’s global strategic layout. Leveraging its profound technical expertise in core bioprocessing equipment, modular turnkey plant solutions, and digital-intelligent factories, Morimatsu has been deeply involved in the construction of multiple benchmark biopharmaceutical facilities in Singapore. The company has effectively facilitated the rapid deployment of local biopharma production capacity, accumulating extensive engineering and practical experience in the Asia-Pacific biopharmaceutical sector.
As a new member of the BioPIPS, Morimatsu will fully leverage its strengths in engineering technology and industrial commercialization to actively participate in the alliance’s key initiatives:
1.Flexible and Agile Manufacturing
Delivering modular and rapidly scalable biopharmaceutical plant solutions to flexibly accommodate the diverse production needs of multi-product biologics.
2.Manufacturing Efficiency Enhancement
Collaborating across industry, academia, and research institutions to conduct joint technical explorations on cutting-edge topics such as digital-intelligent processes and data-driven production, thereby elevating overall manufacturing efficiency.
3.Green and Sustainable Production
Promoting low-carbon design for pharmaceutical plants and utilizing technological innovation to reduce costs and resource consumption in biomanufacturing, putting the concept of sustainable development into practice.
4.Supply Chain Collaborative Innovation
Closely aligning with the alliance’s cutting-edge research achievements to accelerate the translation of innovative technologies from the laboratory to industrial application, seamlessly bridging the innovation chain with the industrial chain.
Moving forward, Morimatsu will join hands with global partners within the BioPIPS ecosystem to build a solid bridge between scientific innovation and engineering implementation. By collectively tackling pain points in biomanufacturing, Morimatsu is committed to delivering more competitive biopharmaceutical solutions, continuously empowering the robust development of the Asia-Pacific biopharma industry, and ultimately benefiting patients worldwide.
About Morimatsu LifeSciences
Morimatsu LifeSciences is a key business segment of Morimatsu International Holdings Limited (Stock Code: 2155.HK). It comprises Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) LifeSciences Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Shanghai Mori-Biounion Technology Co., Ltd., Shanghai Morisora Technology Co., Ltd., Bioengineering AG, Pharmadule Morimatsu AB, and its affiliated companies.
Morimatsu LifeSciences is dedicated in providing core equipment, process systems, and smart modular facility solutions, and services for the pharmaceutical, biopharmaceutical, medical aesthetics, and fast-moving consumer goods (FMCG) sectors including (cosmetics, food, and health supplements), as well as data centers.
Our team comprises highly experienced professionals with deep expertise in process R&D, engineering design, advanced manufacturing, compliance and validation consulting, production execution, and intelligent operations. With broad experience across diverse industries, we fully understand the unique characteristics and process requirements of various products. This enables us to deliver tailored, end-to-end process solutions from the conceptual design stage, precisely aligned with client’s specific needs.
Morimatsu LifeSciences has established a strong global presence, supported by advanced R&D centers, design hubs, and state-of-the-art manufacturing facilities worldwide. Our well-established service network spans Europe,USA,Asia-Pacific, and emerging markets. We have successfully delivered outstanding, customized solutions to clients in over 40 countries and regions, gaining extensive experience in international project execution.
As a multinational enterprise with core strengths in process technology, modular facility construction, and intelligent manufacturing, Morimatsu LifeSciences is dedicated to meeting the evolving equipment and system needs of our key industries. Through continuous innovation and technological advancement, we are steadily expanding our global footprint, driving our international strategy forward, and delivering Morimatsu’s expertise, reliability, and innovation to the global life sciences and related sectors.
